TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34184823
Drug: Sodium-glucose co-transporter
Normalized name: Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Study: 34535959
Drug: Glycine supplementation
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine supplementation (7 g twice daily for 4 months)
Study: 34535959
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (7 g twice daily for 4 months)
Study: 33723086
Drug: Axxess bifurcation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axxess bifurcation device (Biosensors) in combination with Absorb BVS (Abbott Vascular)
Study: 35704479
Drug: HSIL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSIL treatment (including office-based ablative procedures, ablation or excision under anesthesia, or topical fluorouracil or imiquimod)
Study: 35704479
Drug: Active monitoring
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active monitoring without treatment
Study: 36031439
Drug: TXA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (10 mg/kg bolus dose 15 min prior to incision and another similar dose after 3 h)
Study: 35909585
Drug: Traditional breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional breathing therapy (TG)
Study: 32720582
Drug: High-intensity statin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin, ezetimibe, and high-dose proprotein convertase subtilisin/kexin type 9 inhibitor
Study: 35082351
Drug: Physical-possession condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical-possession condition (participants possessed a tangible placebo analgesic oil)
Study: 35082351
Drug: Psychological-possession condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological-possession condition (participants possessed a coupon for a placebo analgesic oil)
Study: 33548329
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.5 mg dexamethasone and 800 mg ibuprofen
Study: 33164611
Drug: Upadacitinib 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 7.5 mg daily
Study: 33164611
Drug: Methotrexate 7.5
Normalized name: methotrexate 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 7.5 mg/week (titrated to ≤15 mg/week)
Study: 36148320
Drug: 3 μg/(kg·min)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 μg/(kg·min) mivacurium (group M1)
Study: 36148320
Drug: 6 μg/(kg·min)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 μg/(kg·min) mivacurium (group M2)
Study: 36148320
Drug: 9 μg/(kg·min)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 μg/(kg·min) mivacurium (group M3)
Study: 35904950
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy followed by laser therapy (980 nm DL, 1 W, continuous wave mode, 20 sec per tooth side, repeated twice at 5‐7 day intervals)
Study: 35904950
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal therapy followed by laser therapy
Study: 32412917
Drug: Prescription Tongxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription Tongxin
Study: 32412917
Drug: Shexiang Baoxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Baoxin Pill
Study: 32484850
Drug: SENATOR software-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SENATOR software-guided medication optimization plus standard care
Study: 33542551
Drug: Partial cystectomy
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial cystectomy and adjunctive medical therapy (Group A)
Study: 33542551
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (Group B)
Study: 32074624
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT) + Treatment as Usual (TAU)
Study: 32074624
Drug: Specialized Attention
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized Attention Therapy (SAT) + Treatment as Usual (TAU)
Study: 35651925
Drug: Traditional drug
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional drug therapy
Study: 36082508
Drug: NRPT 1X
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRPT 1X (recommended daily dose)
Study: 36082508
Drug: NRPT 2X
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRPT 2X (double dose)
Study: 35410939
Drug: internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet-delivered cognitive behavioural therapy (iCBT)
Study: 34111898
Drug: Tablet Computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Computer
Study: 34111898
Drug: Both Robot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Robot and Tablet
Study: 36372250
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified EPA (1800 mg/day)
Study: 38656736
Drug: BI 1358894
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1358894 (100 mg)
Study: 38421881
Drug: Ensartinib 225
Normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensartinib 225 mg orally once daily
Study: 35315257
Drug: Esaxerenone 5-mg
Normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Esaxerenone 5-mg orally disintegrating tablet (ODT) taken with water
Study: 35315257
Drug: Esaxerenone 5-mg
Normalized name: Esaxerenone
DrugBank: Esaxerenone (DB15207)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Esaxerenone 5-mg orally disintegrating tablet (ODT) taken without water
Study: 35315257
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral tablet (5-mg)
Study: 33180929
Drug: Vi‐tetanus toxoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi‐tetanus toxoid conjugate (Vi‐TT) vaccine
Study: 33180929
Drug: Vi‐polysaccharide (Vi‐PS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi‐polysaccharide (Vi‐PS) vaccine
Study: 33180929
Drug: Vi‐TT and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi‐TT and Vi‐PS vaccines (combined analysis)
Study: 34506037
Drug: Prophylactic closed-incision
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic closed-incision negative pressure wound therapy dressing
Study: 35724467
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no prophylactic treatment)
Study: 35489376
Drug: NVX-CoV2373 vaccine
Normalized name: SARS-CoV-2 NVX-CoV2373 vaccine, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 vaccine (5 µg SARS-CoV-2 recombinant spike protein with 50 µg Matrix-M adjuvant)
Study: 33517233
Drug: Nicotine cigarettes
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine cigarettes (various contents: 1.3, 2.3, 5.5, 11.2, and 17.4 mg/g)
Study: 33517233
Drug: Very Low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg/g)
Study: 35388471
Drug: Nirmatrelvir/ritonavir (300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirmatrelvir/ritonavir (300/100 mg b.i.d.)
Study: 32554835
Drug: Traditional Persian
Normalized name: PERUVIAN BALSAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Persian medicine (TPM) strategies including exercise, nutrition, massage, bathing, aromatherapy, and sleeping.
Study: 32553329
Drug: Second-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation drug-eluting stents (DES)
Study: 32750393
Drug: 1-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1-month dual anti-platelet therapy (DAPT) followed by 23-month ticagrelor monotherapy
Study: 32750393
Drug: 12-month dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12-month dual anti-platelet therapy (DAPT) followed by 12-month aspirin monotherapy
Study: 35289296
Drug: Triple Therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Therapy (TT)
Study: 35822607
Drug: LIA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIA with a new cocktail containing ropivacaine, diprospan, and morphine
Study: 32349698
Drug: Social Activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Activity Therapy (SAT)
Study: 35977911
Drug: Beta-alanine supplementation
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine supplementation (3.2 g/day for 12 weeks)
Study: 35665223
Drug: Tangeretin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangeretin (200 mg/day)
Study: 33213494
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHu‐EPO) 10000 IU subcutaneous injection after operation and once daily for the next week
Study: 33808652
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K (400 µg MK‐7/day) and vitamin D3 (80 µg/day)
Study: 33754184
Drug: Enteral resorbable
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral resorbable diet (ED) with peristalsis-inhibiting medication
Study: 33100212
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream of Malva sylvestris extract, applied twice daily for 4 weeks.
Study: 33100212
Drug: Placebo cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream, applied twice daily for 4 weeks.
Study: 33188138
Drug: Intramuscular ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceftriaxone followed by 5 days of azithromycin and metronidazole (IA)
Study: 33957190
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Education Program combined with routine dental treatment (OHEPDT)
Study: 33957190
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment alone (DT)
Study: 33931498
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 5), Paclitaxel (175 mg/m2), and Bevacizumab (15 mg/kg) for six 3-weekly cycles followed by Bevacizumab single agent (15 mg/kg) until progression or unacceptable toxicity
Study: 34154431
Drug: 4-month physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month physical activity group program (two walks per week and a monthly visit to a sociocultural facility)
Study: 35246243
Drug: Diacerein 50
Normalized name: Diacerein 50 mg and glucosamine sulfate potassium chloride 1.5 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein 50 mg once-daily (n=18)
Study: 32946077
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg, Cialis®)
Study: 32946077
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Tadalafil and Placebo)
Study: 37034122
Drug: Lobeglitazone monotherapy
Normalized name: lobeglitazone
DrugBank: Lobeglitazone (DB09198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone monotherapy
Study: 34812472
Drug: Combination taping
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination taping
Study: 35720389
Drug: Intranasal anti-SARS-CoV-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal anti-SARS-CoV-2 RBD IgY
Study: 34259850
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (electrotherapy and oral medication)
Study: 35443106
Drug: AZD7442 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7442 (300 mg, two consecutive intramuscular injections of tixagevimab and cilgavimab)
Study: 35443106
Drug: AZD7442 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7442 (300 mg)
Study: 36890535
Drug: Nurse-administered injections
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered injections
Study: 35550707
Drug: 6% Pueraria
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% Pueraria mirifica vaginal gel
Study: 32081463
Drug: mirvetuximab soravtansine
Normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirvetuximab soravtansine (6 mg/kg, adjusted ideal body weight) and bevacizumab (15 mg/kg)
Study: 36670359
Drug: Clarithromycin, esomeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, esomeprazole, and amoxicillin
Study: 36670359
Drug: Levofloxacin, esomeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin, esomeprazole, and amoxicillin
Study: 35091442
Drug: Ponatinib 45
Normalized name: PONATinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45 mg once daily
Study: 36163905
Drug: Ponatinib 30
Normalized name: PONATinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 30 mg once daily
Study: 36163905
Drug: Ponatinib 15
Normalized name: PONATinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 15 mg once daily
Study: 34407543
Drug: Ponatinib 45
Normalized name: PONATinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45 mg and 30 mg (reduced to 15 mg upon response)
Study: 32928279
Drug: GV‐971 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV‐971 600 mg
Study: 32928279
Drug: GV‐971 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV‐971 900 mg
Study: 33538686
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy, titrated to the British Thoracic Society's peripheral oxygen saturation targets
Study: 34967444
Drug: Best Possible
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Possible Medication History (BPMH) approach
Study: 36099408
Drug: Preoperative respiratory
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative respiratory therapy (EG)
Study: 33813141
Drug: Flexyn2a bioconjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexyn2a bioconjugate vaccine
Study: 32027212
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (intensive medical therapies)
Study: 36378059
Drug: Liu-zi-jue plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liu-zi-jue plus conventional therapy
Study: 33415873
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus medication (1% lidocaine 4 mL after acupuncture)
Study: 33415873
Drug: Simple medication
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple medication (1% lidocaine 30 mL)
Study: 33934988
Drug: Volatile Anesthetics
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile Anesthetics exposure quantified using area under the end-tidal expired anesthetic agent versus time curves
Study: 36098133
Drug: Bimagrumab 210
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 210 mg
Study: 36098133
Drug: Bimagrumab 700
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 700 mg
Study: 36098133
Drug: Bimagrumab 70
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab 70 mg
Study: 32347763
Drug: Dupilumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab (300 mg subcutaneously weekly or every 2 weeks)
Study: 32347763
Drug: Dupilumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab with concomitant topical corticosteroids (TCS)
Study: 32347763
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (TCS) alone
Study: 35842816
Drug: Ivermectin/praziquantel (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin/praziquantel (0.2 mg/kg)
Study: 35842816
Drug: Moxidectin/praziquantel (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin/praziquantel (0.4 mg/kg)
Study: 35325108
Drug: CC‐486 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC‐486 (oral azacitidine) 300 mg daily in a 2 weeks on/2 weeks off schedule
Study: 34097069
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) along with Pregabalin
Study: 35249270
Drug: Metformin add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin add-on insulin therapy
Study: 35973668
Drug: Riboflavin 50
Normalized name: riboflavin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 50 mg daily
Study: 35973668
Drug: Riboflavin 100
Normalized name: riboflavin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 100 mg daily
Study: 33472913
Drug: Guadecitabine 20
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 20 mg/m2, days 1-5, combined with gemcitabine (1,000 mg/m2, i.v., days 8 + 15) and cisplatin (70 mg/m2, i.v., day 8)
Study: 35394800
Drug: selinexor (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: selinexor (60 mg) twice weekly in 6-week cycles
Study: 34097045
Drug: HMGCR GRS
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMGCR GRS equivalent to a 10‐mg/dL decrease in LDL cholesterol
Study: 32605578
Drug: Bifidobacterium quadruple
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium quadruple viable tablet
Study: 35107050
Drug: AVT02 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVT02 (40 mg dose)
Study: 35107050
Drug: EU-reference product
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EU-reference product (adalimumab) (40 mg dose)
Study: 35107050
Drug: US-reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-reference product (adalimumab) (40 mg dose)
Study: 35107050
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (AVT02, EU-reference, US-reference)
Study: 32576225
Drug: Atezolizumab (anti-PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (anti-PD-L1 antibody)
Study: 32576225
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle) + Atezolizumab
Study: 32576225
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD 20 mg/m2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle) + Placebo
Study: 34742230
Drug: LTN 200
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTN 200 mg
Study: 34742230
Drug: LTN 100
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTN 100 mg
Study: 34742230
Drug: LTN 200
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTN 200 mg, LTN 100 mg, LTN 50 mg
Study: 35414799
Drug: Probiotics combined
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics combined with standard triple therapy (Group B)
Study: 35414799
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (Group A)
Study: 32252103
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of multi-joint and single-joint (MJ+SJ) exercises
Study: 34986506
Drug: SQ sublingual
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ sublingual immunotherapy tablets for grass pollen allergy
Study: 34986506
Drug: SQ sublingual
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ sublingual immunotherapy tablets for tree pollen allergy
Study: 32348531
Drug: Anti-VEGF agents
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF agents
Study: 33496413
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 mg / kg / h)
Study: 33496413
Drug: Remifentanil (50‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (50‐100 μg / kg / h)
Study: 32805184
Drug: Statin+high‐dose EPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin+high‐dose EPA (1800 mg/day)
Study: 32805184
Drug: Statin+EPA (930
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin+EPA (930 mg/day)+DHA (750 mg/day)
Study: 33034747
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT (ULD CT)
Study: 34755785
Drug: Ibuprofen/Caffeine
Normalized name: Ibuprofen/Caffeine/Vitamins B1, B2, B6, & B12 400 mg-65 mg-25 mg-6.25 mg-25 mg-125 mcg ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/Caffeine
Study: 35272897
Drug: Intraosseous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous morphine (10 mg) with standard IO antibiotic injection